Insmed Inc (INSM)vsNewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
NAMS
NewAmsterdam Pharma Company N.V. Ordinary Shares
$31.01
+3.16%
HEALTHCARE · Cap: $3.46B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 2595% more annual revenue ($606.42M vs $22.50M). NAMS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
NAMS
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -28.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : NAMS
The strongest argument for NAMS centers on Altman Z-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : NAMS
The primary concerns for NAMS are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while NAMS is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
NAMS generates stronger free cash flow (-41M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
NewAmsterdam Pharma Company N.V. Ordinary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
NewAmsterdam Pharma Company N.V. is a groundbreaking biotechnology firm specializing in the development of innovative therapies for cardiometabolic diseases. Utilizing its proprietary technology platform, the company addresses critical unmet medical needs with a focus on advanced drug discovery and a robust clinical development pipeline. Led by a team of experienced industry professionals, NewAmsterdam is strategically positioned to become a key player in the biopharmaceutical landscape, presenting investors with a compelling growth opportunity through its novel therapeutic initiatives aimed at transforming treatment paradigms and enhancing patient outcomes.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?